CRISPR Therapeutics AG
NASDAQ:CRSP
| Market Cap (Intraday) | 8.40B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $119.24 |
| 50-Day MA | $135.97 |
| 200-Day MA | $117.71 |
CRISPR Therapeutics AG Stock, NASDAQ:CRSP
Baarerstrasse 14, Zug, Zug 6300
Switzerland
Phone: +41.41.561.32.77
Number of Employees: 410
Description
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.